A recent study published in the journal In Vivo assessed the therapeutic effect of axitinib as a third-line therapy following second-line nivolumab monotherapy in patients with metastatic renal cell carcinoma (RCC).

Data from patients treated with axitinib as a third-line therapy after failure of first-line tyrosine kinase inhibitor (TKI) and second-line nivolumab monotherapy were reviewed. Axitinib showed therapeutic efficacy in terms of progression-free survival, overall survival, and objective response rate as a third-line treatment. However, further studies are needed to confirm these findings.

Read more in In Vivo here